BR102375

®

MedChemExpress

Cat. No.:	HY-128344	
CAS No.:	2366255-59-4	
Molecular Formula:	C ₃₁ H ₃₄ N ₆ O ₄	
Molecular Weight:	554.64	
Target:	PARP; Apoptosis	
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Apoptosis	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	о́́́́́́́́́́́́́́́́́́́́́́́́́́́́́́́́́́́́

Product Data Sheet

BIOLOGICAL ACTIVITY				
Description	BR102375 is a non-TZD peroxisome proliferator-activated receptor γ (PPAR γ) full agonist for the treatment of type 2 diabetes, reveals EC ₅₀ value of 0.28 μM and A _{max} ratio of 98% ^[1] .			
In Vitro	BR102375 (Compound 18) (10 μM) increases gene expression levels relevant to PPARγ activation and enhances glucose uptake under insulin stimulation ^[1] . BR102375 (Compound 18) (10 nM, 100 nM, 1 μM; 6 days, 14 days) shows a concentration-dependent, insulin-sensitive effects on adipogenesis ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCR ^[1]			
	Cell Line:	3T3-L1 mouse preadipocyte cells		
	Concentration:	10 μM		
	Incubation Time:			
	Result:	Increased AP2 and CD36 cells gene mRNA expression and enhanced glucose uptake when stimulated by insulin.		
In Vivo	BR102375 (Compound 18) has decent efficacy on mouse diabetes model ^[1] . BR102375 reveals significant suppressive effect on random blood glucose increase(75 mpk, p.o., bid), shows decent effect on insulin resistance on Oral glucose tolerance test (OGTT) and discloses similar findings in body weight gain almost identical to Pioglitazone ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

CUSTOMER VALIDATION

• Life Sci. 2020 Aug 15;255:117849.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Choung W, et al. Discovery of BR102375, a new class of non-TZD PPARy full agonist for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2019 Jun 19. pii: S0960-894X(19)30407-X.

[2]. Yan Zhu, et al. Protective Role of Long Noncoding RNA CRNDE in Myocardial Tissues From Injury Caused by Sepsis Through the microRNA-29a/SIRT1 Axis. Life Sci. 2020 May 27;117849.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA